Business Context and Reporting Period
This Form 8-K Current Report was filed by RXi Pharmaceuticals Corporation (noting the metadata reference to SELLAS Life Sciences Group, Inc. appears to be a discrepancy as the filing text identifies RXi) on July 30, 2009. The report details a private placement offering of securities under a previously effective Form S-3 Registration Statement.
Key Financial Metrics and Offering Details
- Gross Proceeds: The Company anticipates raising $8,350,002.50.
- Net Proceeds: Estimated at approximately $7,766,500 after deducting placement agent fees and offering expenses.
- Securities Issued: 2,385,715 Units, each consisting of one share of Common Stock and a warrant to purchase 0.40 of a share.
- Offering Price: $3.50 per Unit.
- Warrant Terms: Warrants to purchase up to 954,286 shares; exercisable beginning six months from issuance for a five-year period at an exercise price of $4.50 per share (or 105% of the closing price on July 30, 2009).
- Placement Agent: Rodman & Renshaw, LLC.
Material Changes and Events
The primary event reported is the execution of a Placement Agency Agreement (originally dated March 17, 2009, and amended on May 26, 2009, and July 22, 2009) to sell the Units to certain investors. The filing does not provide comparative financial data (revenue, profit, or cash flow) for prior periods as this is a transactional report rather than a periodic financial statement.
Outlook, Risks, and Management Commentary
Closing Date: The Offering is expected to close on or about August 4, 2009, subject to customary closing conditions.
Contingencies: The issuance of securities is subject to the terms of the Securities Purchase Agreement and the Placement Agency Agreement. The summary of terms is qualified in its entirety by the full text of these agreements filed as exhibits.
Risks: The filing does not explicitly list new risk factors beyond the standard closing conditions and the dilutive nature of the warrant issuance.
Investor Verification Checklist
- Verify the final closing date of the offering, as it is currently estimated for August 4, 2009.
- Confirm the exact exercise price of the warrants, which is tied to the closing price of the Common Stock on July 30, 2009.
- Review the full Placement Agency Agreement (Exhibit 1.1) and Securities Purchase Agreement (Exhibit 10.1) for specific covenants and conditions.
- Check the press release (Exhibit 99.1) for any additional commentary on the use of proceeds.